5.55

0.18% 0.010

After Hours: 5.40 -0.15 -2.70%

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is traded at $5.55, with a volume of 430.72K. It is up +0.18% in the last 24 hours and down -1.60% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Previous Close:

$5.54

Open:

$5.51

24h Volume:

430.72K

Relative Volume:

0.30

Market Cap:

$381.13M

Revenue:

$380.79M

Net Income/Loss:

$49.27M

P/E Ratio:

-4.4758

EPS:

-1.24

Net Cash Flow:

$10.68M

1W Performance:

-1.94%

1M Performance:

-1.60%

6M Performance:

+222.67%

1Y Performance:

-60.97%

1-Day Range:

$5.45

$5.616

1-Week Range:

$5.32

$5.85

52-Week Range:

$1.575

$19.95

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1203)

Industry

Biotechnology (683)

Phone

617-683-0917

Address

43 THORNDIKE STREET, CAMBRIDGE

Employee

384

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

AMLX's Discussions on Twitter

Compare AMLX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMLX Amylyx Pharmaceuticals Inc	5.55	381.13M	380.79M	49.27M	10.68M	0.70
VRTX Vertex Pharmaceuticals Inc	465.73	119.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	762.34	82.77B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	617.49	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.01	32.63B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.20	28.10B	3.30B	-501.07M	1.03B	-2.1146

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy
Mar-18-24	Downgrade	Mizuho	Buy → Neutral
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

Nov 27, 2024

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire

Nov 27, 2024

Alpha Wave Global LP Invests $2.17 Million in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat

Nov 27, 2024

PTC halts development of ALS drug after trial miss - The Pharma Letter

Nov 27, 2024

Nov 26, 2024

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 26, 2024

Nov 25, 2024

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along - Seeking Alpha

Nov 25, 2024

Connor Clark & Lunn Investment Management Ltd. Has $2.85 Million Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat

Nov 25, 2024

Nov 24, 2024

Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise - MSN

Nov 24, 2024

Nov 21, 2024

Goldman Sachs reiterates Neutral on Amylyx stock, target unchanged amid PBH market uncertainties - Investing.com Nigeria

Nov 21, 2024

Nov 19, 2024

Baird R W Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) to Strong-Buy - MarketBeat

Nov 19, 2024

Baird Upgrades Amylyx Pharmaceuticals (AMLX) - MSN

Nov 19, 2024

Nov 18, 2024

Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha

Nov 18, 2024

Robert W. Baird Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) to "Outperform" - MarketBeat

Nov 18, 2024

Nov 15, 2024

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat

Nov 15, 2024

Nov 11, 2024

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Nov 09, 2024

Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $12.00 Price Target at HC Wainwright - MarketBeat

Nov 08, 2024